Acesso livre
Acesso livre

Infectologia

Estudo randomizado | Reforço de vacinação heterólogo (Pfizer, J&J ou AstraZeneca) vs. homólogo em pessoas que receberam previamente 2 doses da vacina CoronaVac no Brasil.

28 Jan, 2022 | 15:47h

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study – The Lancet

Comentários:

Boosting immunity after CoronaVac – The Lancet

Covid-19: CoronaVac immunity is strongest after boosting with a different vaccine – The BMJ

Estudo relacionado: Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination – Nature Medicine

 

Comentário no Twitter

 

Estudo de coorte | Entre sobreviventes de tratamento em UTI para COVID-19, 75% ainda relatam sintomas físicos, mentais e cognitivos depois de 1 ano.

28 Jan, 2022 | 15:45h

Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19 – JAMA

Comentários:

75% of COVID ICU survivors have physical symptoms 1 year on – CIDRAP

Majority of COVID-19 survivors experience health problems one-year post ICU admission – News Medical

Casos de miocardite relatados após vacinação contra COVID-19 baseada em mRNA nos EUA de dezembro de 2020 até agosto de 2021.

28 Jan, 2022 | 15:43h

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 – JAMA

Comentário: COVID 19: Risk of Myocarditis Highest Following Second Vaccine Dose Among Adolescent and Young Adult Males – MedicalResearch.com

Conteúdos relacionados:

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Enquanto Pfizer e BioNTech iniciam um estudo clínico de vacina baseada na variante Ômicron, não se tem clareza quanto ao tempo para autorização.

28 Jan, 2022 | 15:41h

As Pfizer and BioNTech begin clinical trial of Omicron-based vaccine, timeline to authorization is unclear – STAT

Ver também:

Pfizer begins testing omicron-matched COVID shots in adults – Associated Press

Pfizer and BioNTech start trials of new Omicron-specific jab – BBC

Pfizer and BioNTech begin testing an omicron-specific COVID-19 vaccine – NPR

Deltacron: a história da variante que não ocorreu.

28 Jan, 2022 | 15:39h

Deltacron: the story of the variant that wasn’t – Nature

Opinião | Prevenção da transmissão do SARS-CoV-2 em ambientes de cuidados em saúde no contexto da variante Ômicron.

28 Jan, 2022 | 15:38h

Preventing SARS-CoV-2 Transmission in Health Care Settings in the Context of the Omicron Variant – JAMA

 

Comentário no Twitter

 

[Preprint] Alta prevalência de distúrbios do olfato 18 meses depois do contágio pela COVID-19.

28 Jan, 2022 | 15:36h

High prevalence of olfactory disorders 18 months after contracting COVID-19 – medRxiv

Comentários:

Half of first-wave Covid cases may have lasting harm to sense of smell – The Guardian

Prevalence of olfactory dysfunction 18 months after SARS-CoV-2 infection – News Medical

Estudo randomizado | Terapia de observação eletrônica direta é não inferior à terapia de observação pessoal para garantir a adesão ao tratamento da tuberculose.

28 Jan, 2022 | 15:30h

In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial – JAMA Network Open

 

Comentário no Twitter

 

Um estudo de registro com 1.581 casos de Stenotrophomonas maltophilia sanguínea e/ou infecções de trato respiratório inferior sugere que levofloxacino é uma alternativa razoável à terapia padrão com trimetoprima-sulfametoxazol.

28 Jan, 2022 | 15:19h

Trimethoprim-Sulfamethoxazole versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 U.S. Hospitals – Open Forum Infectious Diseases

 

Comentário no Twitter

 

Febre de origem indeterminada e incidência de câncer: um estudo de coorte de base populacional usando registros nacionais da Dinamarca mostrou que o risco de câncer em 1 ano foi de 1,2%.

28 Jan, 2022 | 15:18h

Fever of unknown origin and incidence of cancer – Clinical Infectious Diseases (link para o resumo – $ para o texto completo)

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.